LSB
LakeShore Biopharma Co., Ltd·Healthcare
0.63
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.5752W H: $8.60
LSB NEWS
businesswire.com
Apr 2
LSB Industries, Inc. Appoints Jonathan Ackerman as an Independent Member of the Board of Directors; Announces Retirement of Steve Packebush
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced that it has appointed Jonathan Z. Ackerman as an independent member of the Board of Directors (the “Board”) effective April 2, 2026. Mr. Ackerman will stand for direct election by shareholders for the first time at the annual meeting of stockholders on May 21, 2026 (the “2026 Annual Meeting”). Mr. Ackerman has a lengthy track record as a successful leader in infrastructure development and.
prnewswire.com
Mar 25
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special Committee") has received a revised preliminary non-binding proposal letter (the "Proposal Letter"), dated March 24, 2026, from Oceanpine Skyline Inc. ("Parent") and Oceanpine Merger Sub Inc. ("Merger Sub"), to reduce the purchase price for acquiring all of the outstanding ordinary shares of the Company (the "Ordinary Shares") that are not currently owned by Parent, Merger Sub, the Rollover Shareholders (as defined in the Agreement and Plan of Merger, dated November 4, 2025, by and among the Company, Parent and Merger Sub), or their respective affiliates, to US$0.06 per Ordinary Share (the "Proposed Transaction"). A copy of the Proposal Letter is attached hereto as Exhibit A.
seekingalpha.com
Feb 28
LSB Industries: Strong 2025 And Massive NOLs Lead To Poison Pill Defense
LSB Industries is upgraded to buy after strong FY25 results, robust NOL carryforwards, and an optimistic 2026 outlook. LXU reported FY25 revenues up 22.3% YoY and EPS of $0.22, beating estimates, with EBITDA up 25% and further improvements targeted. Substantial NOLs ($243.9M federal, $342.7M state) are protected by a poison pill, enhancing future tax efficiency and takeover defense.
businesswire.com
Feb 25
LSB Industries, Inc. Reports Operating Results for the 2025 Fourth Quarter and Full Year and Provides Product Sales Volume Outlook for 2026
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Results and Recent Highlights Net sales of $165.0 million compared to $134.9 million in the fourth quarter of 2024 Net income of $16.1 million compared to a net loss of $9.1 million in the fourth quarter of 2024 Diluted EPS of $0.22 compared to $(0.13) for the fourth quarter of 2024.
businesswire.com
Feb 11
LSB Industries, Inc. Schedules 2025 Fourth Quarter and Full Year Results Release for Wednesday, February 25th and Conference Call for Thursday, February 26th
OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025 on February, 25, 2026 after the close of the stock market. LSB's management will host a conference call on Thursday, February, 26, 2026 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman & Chief Executive Officer, Mark Behrman, Executive Vice President &a.
prnewswire.com
Feb 6
LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders
BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a notice, dated February 4, 2026, from legal counsel to a group (the "Buyer Group") consisting of Oceanpine Skyline Inc. ("Parent"), Oceanpine Merger Sub Inc. ("Merger Sub"), Oceanpine Capital Inc., Oceanpine Investment Fund II LP, Crystal Peak Investment Inc., Adjuvant Global Health Technology Fund, L.P., Adjuvant Global Health Technology Fund DE, L.P.
